临床肺科杂志
臨床肺科雜誌
림상폐과잡지
JOUNAL OF CLINICAL PULMONARY MEDICINE
2015年
2期
216-219
,共4页
胰岛素泵%肺结核%2型糖尿病
胰島素泵%肺結覈%2型糖尿病
이도소빙%폐결핵%2형당뇨병
insulin pump%tuberculosis%type 2 diabetes
目的:探讨胰岛素泵治疗肺结核合并糖尿病患者的临床效果。方法将初治菌阳空洞性肺结核合并2型糖尿病患者随机分为持续皮下胰岛素输注组(CSII组)、多次皮下胰岛素注射组(MSII组)、口服降糖药物治疗组(OAD组),比较观察三组患者治疗前及治疗2个月后血糖控制情况、痰菌转阴率、病灶吸收有效率、空洞闭合率等方面的差异。结果 CSII组、MSII组在血糖控制、痰菌转阴率、病灶吸收有效率、空洞闭合率均显著高于OAD组,CSII组胰岛素用量、血糖达标时间显著优于MSII组。结论胰岛素泵治疗肺结核合并糖尿病,在平稳有效安全降糖的同时更有利于促进痰菌转阴。
目的:探討胰島素泵治療肺結覈閤併糖尿病患者的臨床效果。方法將初治菌暘空洞性肺結覈閤併2型糖尿病患者隨機分為持續皮下胰島素輸註組(CSII組)、多次皮下胰島素註射組(MSII組)、口服降糖藥物治療組(OAD組),比較觀察三組患者治療前及治療2箇月後血糖控製情況、痰菌轉陰率、病竈吸收有效率、空洞閉閤率等方麵的差異。結果 CSII組、MSII組在血糖控製、痰菌轉陰率、病竈吸收有效率、空洞閉閤率均顯著高于OAD組,CSII組胰島素用量、血糖達標時間顯著優于MSII組。結論胰島素泵治療肺結覈閤併糖尿病,在平穩有效安全降糖的同時更有利于促進痰菌轉陰。
목적:탐토이도소빙치료폐결핵합병당뇨병환자적림상효과。방법장초치균양공동성폐결핵합병2형당뇨병환자수궤분위지속피하이도소수주조(CSII조)、다차피하이도소주사조(MSII조)、구복강당약물치료조(OAD조),비교관찰삼조환자치료전급치료2개월후혈당공제정황、담균전음솔、병조흡수유효솔、공동폐합솔등방면적차이。결과 CSII조、MSII조재혈당공제、담균전음솔、병조흡수유효솔、공동폐합솔균현저고우OAD조,CSII조이도소용량、혈당체표시간현저우우MSII조。결론이도소빙치료폐결핵합병당뇨병,재평은유효안전강당적동시경유리우촉진담균전음。
Objective To investigate the clinical efficacy of insulin pump in the treatment of diabetic pa-tients complicated with pulmonary tuberculosis.Methods The initial treatment of bacillary cavitary pulmonary tu-berculosis patients complicated with type 2 diabetes were randomly divided into the continuous subcutaneous insulin infusion group (the CSII group),the multiple subcutaneous insulin injection group (the MSII group),and the oral hypoglycemic drug treatment group (the OAD group).Their glycemic control,sputum negative conversion,lesions absorption and cavity closure rate were compared among the three groups before and 2 months after the treatment.Re-sults The glycemic control,sputum negative conversion,lesions absorption and cavity closure rate blood glucose were significantly better in the CSII group and the MSII group than in the OAD group,and the usage of insulin and the time of blood sugar back to normal were better in the CSII group than in the MSII group.Conclusion CSII can achieve stable and effective glucose control and promote negative sputum in the treatment of pulmonary tuberculosis patients complicated with type 2 diabetes mellitus.